Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.
|Poll|February 10, 2023
Poll results: Have you referred a patient with AMD for a low vision evaluation?
Author(s)Kassi Filkins, Editor
See the results from our recent poll!
Advertisement
Optometry Times asked our audience, "Have you referred a patient with AMD for a low vision evaluation?" and the results are in!
The poll appeared on OptometryTimes.com and was promoted across social channels from Feb. 1 to Feb. 7, 2023.
8 ODs responded:
- 7 said they have referred patients and their patients have followed through
- 1 said they have referred a patient and saw no follow through
- No one said they have not referred patients
Curious to learn more about AMD and low vision management?
Advertisement
Related to this article
Are our children truly ready to see—and learn?
Eric Schmidt, OD, FAAO, presented his poster "Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Central Corneal Staining: Phase 3 Pool" at AAOpt 2026.
A young woman had years of headaches, dizziness, and intolerance of her phone despite normal routine eye examinations. A modest prism gave her immediate relief.
Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.
Sherrol Reynolds, OD, FAAO, details her session "GLP-1RAs and Ocular Health: AOA Guidance for Optometric Practice 2025" during AAOpt 2026.
Phil Rainey, OD, MPH, FAAO, states that the recent parameter expansion of Johnson & Johnson's Acuvue Oasys Max 1-Day and Oasys 1-Day has been a game changer for his practice.
A pair of cases from Academy 2026 show scleral lens refits for severe keratoconus, one addressing focal corneal edema and one fitting around glaucoma tube shunts.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Demodex tied to worse MGD as dry eye questionnaires miss blepharitis
2
AAOpt 2026: The real-world impact of treatment switch to latanoprostene bunod
3
AAOpt 2026: Aflibercept 8 mg extends RVO dosing as Amsler misses AMD damage
4
AAOpt 2026: GLP-1RAs and ocular health
5